1 Yang Y, Qi J, Wang Q, Du L, Zhou Y, et al. (2013) Berberine suppresses Th17 and dendritic cell responses. Invest Ophthalmol Vis Sci 54: 2516-2522.

2Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, et al. (2011) Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30: 61-69.

3Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, et al. (2014) Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs 6: 1190-1200.

1 Yang Y, Qi J, Wang Q, Du L, Zhou Y, et al. (2013) Berberine suppresses Th17 and dendritic cell responses. Invest Ophthalmol Vis Sci 54: 2516-2522.

2Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, et al. (2011) Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30: 61-69.

3Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, et al. (2014) Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs 6: 1190-1200.

4Hasko G, Szabo C (1999) IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. Br J Pharmacol 127: 1295-1304.

5Ledford H (2014) Cancer treatment: The killer within. Nature 508: 24-26.

6Capitini CM, Otto M, DeSantes KB, Sondel PM (2014) Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol 10: 1659-1678.

7Klingemann HG (2013) Cellular therapy of cancer with natural killer cells-where do we stand? Cytotherapy 15: 1185-1194.

8Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, et al. (2000) Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 204: 64-74.

9 Sohn KC, Li ZJ, Choi DK, Zhang T, Lim JW, et al. (2014) Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20. PLoS One 9: e95337.

10Cox O, Velez C, Kumar V, V. Malhotra S, A. Rivera L, et al. (2014) Synthesis of and Biological Study of 7-Benzyl-3-aminobenzimidazo[3,2- a]quinolinium Chloride (ABQ-48: NSC D-763307) and 7-benzyl-3- nitrobenzimidazo[3,2-a]quinolinium Chloride (NBQ 48: NSC D-763303). Current Bioactive Compounds 10: 286-291.

11Garbett NC, Graves DE (2004) Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents 4: 149-172.

12Pereira GC, Branco AF, Matos JA, Pereira SL, Parke D, et al. (2007) Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J Pharmacol Exp Ther 323: 636-649.

13Colon IG, Gonzalez FA, Cordero M, Zayas B, Velez C, et al. (2008) Role of the nitro functionality in the DNA binding of 3-nitro-10-methylbenzothiazolo[3,2-a]quinolinium chloride. Chem Res Toxicol 21: 1706-1715.

14Vélez C, Cox O, Rosado-Berrios C, Molina D, Arroyo L, et al. (2013) Novel nitrobenzazolo[3,2-a]quinolinium salts induce cell death through a mechanism involving DNA damage, cell cycle changes, and mitochondrial permeabilization. Open Journal of Apoptosis 2: 13-22.

15Zayas B, Beyley J, Terron M, Cordero M, Hernandez W, et al. (2007) Comparison of the nucleic acid covalent binding capacity of two nitro-substituted benzazolo[3,2-a]quinolinium salts upon enzymatic reduction. Toxicol In Vitro 21: 1155-1164.

13Colon IG, Gonzalez FA, Cordero M, Zayas B, Velez C, et al. (2008) Role of the nitro functionality in the DNA binding of 3-nitro-10-methylbenzothiazolo[3,2-a]quinolinium chloride. Chem Res Toxicol 21: 1706-1715.

14Vélez C, Cox O, Rosado-Berrios C, Molina D, Arroyo L, et al. (2013) Novel nitrobenzazolo[3,2-a]quinolinium salts induce cell death through a mechanism involving DNA damage, cell cycle changes, and mitochondrial permeabilization. Open Journal of Apoptosis 2: 13-22.

15Zayas B, Beyley J, Terron M, Cordero M, Hernandez W, et al. (2007) Comparison of the nucleic acid covalent binding capacity of two nitro-substituted benzazolo[3,2-a]quinolinium salts upon enzymatic reduction. Toxicol In Vitro 21: 1155-1164.

16Shetty N, Gupta S (2014) Eribulin drug review. South Asian J Cancer 3: 57-59.

17Shen G, Bian G, Yu H, Gao M, Kang D, et al. (2014) Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2: 146-150.

18Stec R, Bodnar L, Smoter M, Korniluk J, Kuchar A, et al. (2014) Mitomycin C and High-Dose 5-Fluorouracil With Folinic Acid as a Therapeutic Option for Heavily Pretreated Patients With Metastatic Colorectal Cancer: Prospective Phase II Trial. Oncologist 19: 356-357.

19Lyman GH, Kuderer NM (2002) Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 62 Suppl 1: 65-78.

20Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, et al. (1998) A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 16: 366-373.

21Gao LL, Huang XE, Zhang Q, Tang JH (2011) A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev 12: 77-80.

22Ray-Coquard I, Paraiso D, Guastalla JP, Leduc B, Guichard F, et al. (2007) Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer 97: 1200-1205.

23Do BH, Ryu HB, Hoang P, Koo BK, Choe H (2014) Soluble prokaryotic overexpression and purification of bioactive human granulocyte colony-stimulating factor by maltose binding protein and protein disulfide isomerase. PLoS One 9: e89906.

24Crawford J (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 30: 24-30.

25Fountzilas G, Skarlos D, Katsohis C, Pavlidis N, Giannakakis T, et al. (1995) High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study. Med Pediatr Oncol 24: 23-28.

23Do BH, Ryu HB, Hoang P, Koo BK, Choe H (2014) Soluble prokaryotic overexpression and purification of bioactive human granulocyte colony-stimulating factor by maltose binding protein and protein disulfide isomerase. PLoS One 9: e89906.

24Crawford J (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 30: 24-30.

25Fountzilas G, Skarlos D, Katsohis C, Pavlidis N, Giannakakis T, et al. (1995) High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study. Med Pediatr Oncol 24: 23-28.

26Iqbal MP, Burney IA (2014) Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase. Pak J Pharm Sci 27: 245-248.

27Berk E, Muthuswamy R, Kalinski P (2012) Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs. Vaccine 30: 6216-6224.

28Ghoneum M, Agrawal S (2011) Activation of human monocyte-derived dendritic cells in vitro by the biological response modifier arabinoxylan rice bran (MGN-3/Biobran). Int J Immunopathol Pharmacol 24: 941-948.

29Maeda H, Uozumi T, Kurisu K, Matsuoka T, Kawamoto K, et al. (1994) Combined antitumor effects of TNF and G-CSF on a human medulloblastoma xenograft line. J Neurooncol 21: 203-213.

30Lopez-Lazaro M (2006) Granulocyte colony-stimulating factor (G-CSF): a novel anticancer therapy based on the "universal dynamics of tumor growth"? Exp Oncol 28: 249-251.